The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways

Journal of Cystic Fibrosis

Volumn 16, Issue 6, 2017, Pages 663-670

  Trend, Stephanie ^a,b   Fonceca, Angela M ^b   Ditcham, William G ^b   Kicic, Anthony ^a,b,c,d,e   CF, AREST ^a,c,f,g  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Antimicrobial; Bacteriophage; Cystic fibrosis; Infection; Phage therapy; Pseudomonas aeruginosa

Indexed keywords

BACTERIOPHAGE; CYSTIC FIBROSIS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; NONHUMAN; ORGANISMAL INTERACTION; PHAGE THERAPY; PSEUDOMONAS INFECTION; RESPIRATORY EPITHELIUM; REVIEW; COMPLICATION; DRUG DELIVERY SYSTEM; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION;

CYSTIC FIBROSIS; DRUG DELIVERY SYSTEMS; HUMANS; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 85023616830     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2017.06.012     Document Type: Review

References (67)

1. Heimeshoff, M., Hollmeyer, H., Schreyogg, J., Tiemann, O., Staab, D., Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre. PharmacoEconomics 30:9 (2012), 763–777.
2. Angelis, A., Kanavos, P., Lopez-Bastida, J., Linertova, R., Nicod, E., Serrano-Aguilar, P., Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom. BMC Health Serv Res, 15, 2015, 428.
3. Sansgiry, S.S., Joish, V.N., Boklage, S., Goyal, R.K., Chopra, P., Sethi, S., Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ 15:2 (2012), 219–224.
4. Emerson, J., Rosenfeld, M., McNamara, S., Ramsey, B., Gibson, R.L., Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 34:2 (2002), 91–100.
5. Al-Aloul, M., Crawley, J., Winstanley, C., Hart, C.A., Ledson, M.J., Walshaw, M.J., Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 59:4 (2004), 334–336.
6. Bradbury, R., Champion, A., Reid, D.W., Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population. Respirology 13:6 (2008), 886–892.
7. Feil, E.J., Li, B.C., Aanensen, D.M., Hanage, W.P., Spratt, B.G., eBURST: inferring patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus sequence typing data. J Bacteriol 186:5 (2004), 1518–1530.
8. Curran, B., Morgan, J.A., Honeybourne, D., Dowson, C.G., Commercial mushrooms and bean sprouts are a source of Pseudomonas aeruginosa. J Clin Microbiol 43:11 (2005), 5830–5831.
9. Drenkard, E., Ausubel, F.M., Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 416:6882 (2002), 740–743.
10. Pillarisetti, N., Williamson, E., Linnane, B., Skoric, B., Robertson, C.F., Robinson, P., et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 184:1 (2011), 75–81.
11. Parkins, M.D., Glezerson, B.A., Sibley, C.D., Sibley, K.A., Duong, J., Purighalla, S., et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol 52:4 (2014), 1127–1135.
12. Kidd, T.J., Ramsay, K.A., Hu, H., Marks, G.B., Wainwright, C.E., Bye, P.T., et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. Eur Respir J 41:5 (2013), 1091–1100.
13. Fothergill, J.L., Walshaw, M.J., Winstanley, C., Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J 40:1 (2012), 227–238.
14. O' Neill, J., The review on antimicrobial resistance. Tackling drug-resistant infections globally: final report and recommendations, 2016 [ http://amr-review.org/sites/default/files/160518_Finalpaper_with cover.pdf].
15. Tai, A.S., Kidd, T.J., Whiley, D.M., Ramsay, K.A., Buckley, C., Bell, S.C., et al. Molecular surveillance for carbapenemase genes in carbapenem-resistant Pseudomonas aeruginosa in Australian patients with cystic fibrosis. Pathology 47:2 (2015), 156–160.
16. Emerson, J., McNamara, S., Buccat, A.M., Worrell, K., Burns, J.L., Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 45:4 (2010), 363–370.
17. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V.A., et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 16:2 (2016), 239–251.
18. Lavigne, R., Lecoutere, E., Wagemans, J., Cenens, W., Aertsen, A., Schoofs, L., et al. A multifaceted study of Pseudomonas aeruginosa shutdown by virulent podovirus luz19. MBio, 4(2), 2013.
19. Hraiech, S., Brégeon, F., Rolain, J.-M., Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des Dev Ther 9 (2015), 3653–3663.
20. Summers, W.C., The strange history of phage therapy. Bacteriophage 2:2 (2012), 130–133.
21. Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One, 4(3), 2009, e4944.
22. Levin, B.R., Bull, J.J., Population and evolutionary dynamics of phage therapy. Nat Rev Microbiol 2:2 (2004), 166–173.
23. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K.C., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109:3 (2002), 317–325.
24. Hanlon, G.W., Denyer, S.P., Olliff, C.J., Ibrahim, L.J., Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl Environ Microbiol 67:6 (2001), 2746–2753.
25. Zegans, M.E., Wagner, J.C., Cady, K.C., Murphy, D.M., Hammond, J.H., O'Toole, G.A., Interaction between bacteriophage DMS3 and host CRISPR region inhibits group behaviors of Pseudomonas aeruginosa. J Bacteriol 191:1 (2009), 210–219.
26. Bryan, D., El-Shibiny, A., Hobbs, Z., Porter, J., Kutter, E.M., Bacteriophage T4 infection of stationary Phase E. coli: life after log from a phage perspective. Front Microbiol, 7, 2016, 1391.
27. van Houte, S., Buckling, A., Westra, E.R., Evolutionary ecology of prokaryotic immune mechanisms. Microbiol Mol Biol Rev 80:3 (2016), 745–763.
28. James, C.E., Fothergill, J.L., Kalwij, H., Hall, A.J., Cottell, J., Brockhurst, M.A., et al. Differential infection properties of three inducible prophages from an epidemic strain of Pseudomonas aeruginosa. BMC Microbiol, 12, 2012, 216.
29. Labrie, S.J., Samson, J.E., Moineau, S., Bacteriophage resistance mechanisms. Nat Rev Microbiol 8:5 (2010), 317–327.
30. Gingeras, T.R., Brooks, J.E., Cloned restriction/modification system from Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 80:2 (1983), 402–406.
31. Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:5819 (2007), 1709–1712.
32. Gasiunas, G., Sinkunas, T., Siksnys, V., Molecular mechanisms of CRISPR-mediated microbial immunity. Cell Mol Life Sci 71:3 (2014), 449–465.
33. Goldfarb, T., Sberro, H., Weinstock, E., Cohen, O., Doron, S., Charpak-Amikam, Y., et al. BREX is a novel phage resistance system widespread in microbial genomes. EMBO J 34:2 (2015), 169–183.
34. Friman, V.P., Soanes-Brown, D., Sierocinski, P., Molin, S., Johansen, H.K., Merabishvili, M., et al. Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J Evol Biol 29:1 (2016), 188–198.
35. Dabrowska, K., Miernikiewicz, P., Piotrowicz, A., Hodyra, K., Owczarek, B., Lecion, D., et al. Immunogenicity studies of proteins forming the T4 phage head surface. J Virol 88:21 (2014), 12551–12557.
36. Majewska, J., Beta, W., Lecion, D., Hodyra-Stefaniak, K., Klopot, A., Kazmierczak, Z., et al. Oral application of T4 phage induces weak antibody production in the gut and in the blood. Virus 7:8 (2015), 4783–4799.
37. Łusiak-Szelachowska, M., Żaczek, M., Weber-Dąbrowska, B., Międzybrodzki, R., Kłak, M., Fortuna, W., et al. Phage neutralization by sera of patients receiving phage therapy. Viral Immunol 27:6 (2014), 295–304.
38. Hodyra-Stefaniak, K., Miernikiewicz, P., Drapala, J., Drab, M., Jonczyk-Matysiak, E., Lecion, D., et al. Mammalian host-versus-phage immune response determines phage fate in vivo. Sci Rep, 5, 2015, 14802.
39. Kazmierczak, Z., Piotrowicz, A., Owczarek, B., Hodyra, K., Miernikiewicz, P., Lecion, D., et al. Molecular imaging of T4 phage in mammalian tissues and cells. Bacteriophage, 4(1), 2014, e28364.
40. Srivastava, A.S., Kaido, T., Carrier, E., Immunological factors that affect the in vivo fate of T7 phage in the mouse. J Virol Methods 115:1 (2004), 99–104.
41. Miernikiewicz, P., Dabrowska, K., Piotrowicz, A., Owczarek, B., Wojas-Turek, J., Kicielinska, J., et al. T4 phage and its head surface proteins do not stimulate inflammatory mediator production. PLoS One, 8(8), 2013, e71036.
42. Bocian, K., Borysowski, J., Zarzycki, M., Wierzbicki, P., Kłosowska, D., Weber-Dąbrowska, B., et al. LPS-activated monocytes are unresponsive to T4 phage and T4-generated Escherichia coli lysate. Front Microbiol, 7, 2016, 1356.
43. Miedzybrodzki, R., Fortuna, W., Weber-Dabrowska, B., Gorski, A., A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med 9:4 (2009), 303–312.
44. Matsuda, T., Freeman, T.A., Hilbert, D.W., Duff, M., Fuortes, M., Stapleton, P.P., et al. Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. Surgery 137:6 (2005), 639–646.
45. Carmody, L.A., Gill, J.J., Summer, E.J., Sajjan, U.S., Gonzalez, C.F., Young, R.F., et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 201:2 (2010), 264–271.
46. Park, K., Cha, K.E., Myung, H., Observation of inflammatory responses in mice orally fed with bacteriophage T7. J Appl Microbiol 117:3 (2014), 627–633.
47. Khan, T.Z., Wagener, J.S., Bost, T., Martinez, J., Accurso, F.J., Riches, D.W., Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151:4 (1995), 1075–1082.
48. Bonfield, T.L., Konstan, M.W., Berger, M., Altered respiratory epithelial cell cytokine production in cystic fibrosis. J Allergy Clin Immunol 104:1 (1999), 72–78.
49. Rosenfeld, M., Gibson, R.L., McNamara, S., Emerson, J., Burns, J.L., Castile, R., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32:5 (2001), 356–366.
50. Sulakvelidze, A., Alavidze, Z., Morris, J.G. Jr., Bacteriophage therapy. Antimicrob Agents Chemother 45:3 (2001), 649–659.
51. Kutateladze, M., Adamia, R., Phage therapy experience at the Eliava Institute. Med Mal Infect 38:8 (2008), 426–430.
52. Kvachadze, L., Balarjishvili, N., Meskhi, T., Tevdoradze, E., Skhirtladze, N., Pataridze, T., et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 4:5 (2011), 643–650.
53. Abedon, S.T., Phage therapy of pulmonary infections. Bacteriophage, 5(1), 2015, e1020260.
54. Saussereau, E., Vachier, I., Chiron, R., Godbert, B., Sermet, I., Dufour, N., et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect 20:12 (2014), O983–O990.
55. Sutanto, E.N., Kicic, A., Foo, C.J., Stevens, P.T., Mullane, D., Knight, D.A., et al. Innate inflammatory responses of pediatric cystic fibrosis airway epithelial cells: effects of nonviral and viral stimulation. Am J Respir Cell Mol Biol 44:6 (2011), 761–767.
56. Alves, M.P., Schogler, A., Ebener, S., Vielle, N.J., Casaulta, C., Jung, A., et al. Comparison of innate immune responses towards rhinovirus infection of primary nasal and bronchial epithelial cells. Respirology 21:2 (2016), 304–312.
57. Schogler, A., Stokes, A.B., Casaulta, C., Regamey, N., Edwards, M.R., Johnston, S.L., et al. Interferon response of the cystic fibrosis bronchial epithelium to major and minor group rhinovirus infection. J Cyst Fibros 15:3 (2016), 332–339.
58. Crabbé, A., Liu, Y., Matthijs, N., Rigole, P., De La Fuente-Nùñez, C., Davis, R., et al. Antimicrobial efficacy against Pseudomonas aeruginosa biofilm formation in a three-dimensional lung epithelial model and the influence of fetal bovine serum. Sci Rep, 7, 2017, 43321.
59. Pirnay, J.-P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., et al. The phage therapy paradigm: Prêt-à-Porter or Sur-mesure?. Pharm Res 28:4 (2011), 934–937.
60. Nobrega, F.L., Costa, A.R., Kluskens, L.D., Azeredo, J., Revisiting phage therapy: new applications for old resources. Trends Microbiol 23:4 (2015), 185–191.
61. Caplan, A., Morals, microbes, and methods. Lancet, 385(9980), 2015, e45.
62. Sahota, J.S., Smith, C.M., Radhakrishnan, P., Winstanley, C., Goderdzishvili, M., Chanishvili, N., et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J Aerosol Med Pulm Drug Deliv, 2015.
63. Golshahi, L., Seed, K.D., Dennis, J.J., Finlay, W.H., Toward modern inhalational bacteriophage therapy: nebulization of bacteriophages of Burkholderia cepacia complex. J Aerosol Med Pulm Drug Deliv 21:4 (2008), 351–360.
64. Semler, D.D., Goudie, A.D., Finlay, W.H., Dennis, J.J., Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother 58:7 (2014), 4005–4013.
65. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., Debarbieux, L., Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One, 6(2), 2011, e16963.
66. Barr, J.J., Auro, R., Furlan, M., Whiteson, K.L., Erb, M.L., Pogliano, J., et al. Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc Natl Acad Sci U S A 110:26 (2013), 10771–10776.
67. Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D., et al. Antipseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob Agents Chemother 60:2 (2015), 744–751.